Does Chemotherapy — Cause Another Cancer?

No. Chemotherapy moves through the bloodstream to reach cancer cells wherever they are — that is the purpose of giving it systemically rather than locally. It does not transport cancer cells from one place to another. If cancer appears at a new site during or after treatment, it was already developing before chemotherapy started. Cancer that has reached multiple sites is called metastatic disease, and that is a property of the original tumour, not something chemotherapy creates.

Yes, and this is documented openly by ASCO and ESMO. A small number of people who receive certain chemotherapy drugs — particularly alkylating agents and topoisomerase II inhibitors — develop a secondary leukaemia, typically years after treatment ends. This is one of the reasons your oncologist considers the lowest effective dose and discusses alternative regimens where they exist. The risk is real, small for most patients, and weighed explicitly against the benefit of treating your primary cancer.

Two groups carry the best-documented risk. Alkylating agents — used in many regimens for lymphoma, breast cancer, and ovarian cancer — are linked to secondary leukaemia appearing several years after treatment. Topoisomerase II inhibitors, used in some breast cancer and leukaemia regimens, carry a risk that can appear sooner. Radiation to certain body areas carries a separate secondary solid-tumour risk. Ask your oncologist which of these apply to the regimen being proposed for you, and what monitoring is planned.

It depends on the drug and the type of secondary cancer. Leukaemia from alkylating agents most commonly appears several years after treatment ends. From topoisomerase II inhibitors it can appear sooner. Radiation-related solid tumours can take a decade or more. This range is why follow-up appointments continue for many years after treatment ends — these are the windows when secondary changes are most likely to be found early, when they are most treatable.

That is a conversation to have with your oncologist, with your specific cancer and proposed drugs on the table. The secondary cancer risk is real but small for most regimens. The risk of an untreated primary cancer is, for most patients, far more immediate and larger. If the information you have been given does not let you make that comparison clearly, ask your team to go through it again. A second opinion from another oncologist is a reasonable step if you remain uncertain.